In a retrospective study by Chiang et al., involving 7651 cancer patients with T2DM receiving immune checkpoint inhibitors, the use of GLP-1 RAs was associated with a reduced risk of MACE (a composite of myocardial infarction, coronary revascularization, heart failure, ischemic stroke, and cardiac arrest) as well as lower all-cause mortality, without an increased risk of serious adverse events [92]. Here, GLP1R is linked to cancer.